Rigel Pharmaceuticals (RIGL) Debt/Equity Ratio: History & Chart

Rigel Pharmaceuticals, Inc.(RIGL)

Biotechnology · South San Francisco, CA

$46.39-1.40 (-2.93%)

Delayed quote: Oct 6, 2026, 3:20 PM EDT

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

South San Francisco, CA

173 employees

www.rigel.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Raul R. Rodriguez

View full financials

RIGL Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.09

DEBT TO EQUITY RATIO AVG TTM

0.32

DEBT TO EQUITY RATIO AVG 3Y

-0.78

DEBT TO EQUITY RATIO AVG 5Y

-0.83

DEBT TO EQUITY RATIO AVG 10Y

0.34

DEBT TO EQUITY RATIO AVG 15Y

0.17

DEBT TO EQUITY RATIO AVG 20Y

0.03

CURRENT VS TTM AVG

-70.78%

CURRENT VS 3Y AVG

+112.08%

CURRENT VS 5Y AVG

+111.37%

CURRENT VS 10Y AVG

-72.53%

CURRENT VS 15Y AVG

-44.82%

CURRENT VS 20Y AVG

+249.69%

SECTOR MEDIAN · HEALTHCARE

0.11

median of 774 covered companies

CURRENT VS SECTOR MEDIAN

-14.63%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Rigel Pharmaceuticals, Inc. (RIGL)	$858.31M	0.09	0.32	-0.78	-0.83
SI-BONE, Inc. (SIBN)vs ›	$856.16M	0.04	0.12	0.21	0.23
QuidelOrtho Corporation (QDEL)vs ›	$852.92M	1.73	1.19	0.87	0.60
Pacific Biosciences of California, Inc. (PACB)vs ›	$851.61M	N/A	71.70	36.60	24.63
SL Science Holding Ltd (SLBT)vs ›	$869.18M	0.09	0.04	0.08	0.08
SpyGlass Pharma, Inc. Common Stock (SGP)vs ›	$840.51M	0.01	N/A	N/A	N/A
Beta Bionics, Inc. (BBNX)vs ›	$830.99M	0.03	0.07	0.07	0.07
Corvus Pharmaceuticals, Inc. (CRVS)vs ›	$880.01M	0.00	0.03	0.03	0.03
Odyssey Therapeutics, Inc. (ODTX)vs ›	$879.93M	0.06	N/A	N/A	N/A
Alumis Inc. (ALMS)vs ›	$831.93M	0.08	0.12	0.12	0.12

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Rigel Pharmaceuticals, Inc. (RIGL)

$858.31M

0.09

0.32

-0.78

-0.83

SI-BONE, Inc. (SIBN)vs ›

$856.16M

0.04

0.12

0.21

0.23

QuidelOrtho Corporation (QDEL)vs ›

$852.92M

1.73

1.19

0.87

0.60

Pacific Biosciences of California, Inc. (PACB)vs ›

$851.61M

N/A

71.70

36.60

24.63

SL Science Holding Ltd (SLBT)vs ›

$869.18M

0.09

0.04

0.08

SpyGlass Pharma, Inc. Common Stock (SGP)vs ›

$840.51M

0.01

N/A

Beta Bionics, Inc. (BBNX)vs ›

$830.99M

0.03

0.07

Corvus Pharmaceuticals, Inc. (CRVS)vs ›

$880.01M

0.00

0.03

Odyssey Therapeutics, Inc. (ODTX)vs ›

$879.93M

0.06

N/A

Alumis Inc. (ALMS)vs ›

$831.93M

0.08

0.12

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Rigel Pharmaceuticals, Inc. (RIGL)?

The debt to equity ratio for RIGL stock is 0.09.

Is Rigel Pharmaceuticals, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 0.09 is 111% above its 5-year average of -0.83, around the middle of its 5-year range (-9.69–18.24).

What is the TTM average debt to equity ratio for Rigel Pharmaceuticals, Inc. (RIGL)?

The TTM average debt to equity ratio for RIGL stock is 0.32.

What is the 3Y average debt to equity ratio for Rigel Pharmaceuticals, Inc. (RIGL)?

The 3Y average debt to equity ratio for RIGL stock is -0.78.

What is the 5Y average debt to equity ratio for Rigel Pharmaceuticals, Inc. (RIGL)?

The 5Y average debt to equity ratio for RIGL stock is -0.83.

What is the 10Y average debt to equity ratio for Rigel Pharmaceuticals, Inc. (RIGL)?

The 10Y average debt to equity ratio for RIGL stock is 0.34.

What is the 15Y average debt to equity ratio for Rigel Pharmaceuticals, Inc. (RIGL)?

The 15Y average debt to equity ratio for RIGL stock is 0.17.

What is the 20Y average debt to equity ratio for Rigel Pharmaceuticals, Inc. (RIGL)?

The 20Y average debt to equity ratio for RIGL stock is 0.03.

DATE	DEBT TO EQUITY RATIO
2026-06-30	0.09
2026-03-31	0.11
2025-12-31	0.14
2025-09-30	0.52
2025-06-30	0.75
2025-03-31	3.29
2024-12-31	18.24
2024-09-30	-4.12
2024-06-30	-2.02
2024-03-31	-1.91
2023-12-31	-2.11
2023-09-30	-1.91
2023-06-30	-2.16
2023-03-31	-2.50
2022-12-31	-3.05
2022-09-30	-2.16
2022-06-30	-9.69
2022-03-31	5.61
2021-12-31	1.01
2021-09-30	0.66
2021-06-30	0.51
2021-03-31	0.47
2020-12-31	1.15
2020-09-30	0.81
2020-06-30	0.68
2020-03-31	0.44
2019-12-31	0.67
2019-09-30	0.55
2019-06-30	0.38
2019-03-31	0.33
2018-12-31	0.00
2018-09-30	0.00
2018-06-30	0.00
2018-03-31	0.00
2017-12-31	0.00
2017-09-30	0.02
2017-06-30	0.03
2017-03-31	0.04
2016-12-31	0.06
2016-09-30	0.06
2016-06-30	0.07
2016-03-31	0.08
2015-12-31	0.03
2015-09-30	0.07
2015-06-30	0.08
2015-03-31	0.08
2014-12-31	0.07
2014-09-30	0.00
2014-06-30	0.00
2014-03-31	0.00
2013-12-31	0.00
2013-09-30	0.00
2013-06-30	0.00
2013-03-31	0.00
2012-12-31	0.00
2012-09-30	0.00
2012-06-30	0.00
2012-03-31	0.00
2011-12-31	0.00
2011-09-30	0.00
2011-06-30	0.00
2011-03-31	0.00
2010-12-31	0.00
2010-09-30	0.01
2010-06-30	0.01
2010-03-31	0.02
2009-12-31	0.02
2009-09-30	0.02
2009-06-30	0.05
2009-03-31	0.04
2008-12-31	0.03
2008-09-30	0.02
2008-06-30	0.01
2008-03-31	0.01
2007-12-31	0.02
2007-09-30	0.02
2007-06-30	0.02
2007-03-31	0.03
2006-12-31	0.03
2006-09-30	0.03
2006-06-30	0.03
2006-03-31	0.03
2005-12-31	0.02
2005-09-30	0.02
2005-06-30	0.07
2005-03-31	0.06
2004-12-31	0.04
2004-09-30	0.04
2004-06-30	0.03
2004-03-31	0.03
2003-12-31	0.09
2003-09-30	0.08
2003-06-30	0.09
2003-03-31	0.28
2002-12-31	0.22
2002-09-30	0.21

DATE

DEBT TO EQUITY RATIO

2026-06-30

0.09

2026-03-31

0.11

2025-12-31

0.14

2025-09-30

0.52

2025-06-30

0.75

2025-03-31

3.29

2024-12-31

18.24

2024-09-30

-4.12

2024-06-30

-2.02

2024-03-31

-1.91

2023-12-31

-2.11

2023-09-30

-1.91

2023-06-30

-2.16

2023-03-31

-2.50

2022-12-31

-3.05

2022-09-30

-2.16

2022-06-30

-9.69

2022-03-31

5.61

2021-12-31

1.01

2021-09-30

0.66

2021-06-30

0.51

2021-03-31

0.47

2020-12-31

1.15

2020-09-30

0.81

2020-06-30

0.68

2020-03-31

0.44

2019-12-31

0.67

2019-09-30

0.55

2019-06-30

0.38

2019-03-31

0.33

2018-12-31

0.00

2018-09-30

0.00

2018-06-30

0.00

2018-03-31

0.00

2017-12-31

0.00

2017-09-30

0.02

2017-06-30

0.03

2017-03-31

0.04

2016-12-31

0.06

2016-09-30

0.06

2016-06-30

0.07

2016-03-31

0.08

2015-12-31

0.03

2015-09-30

0.07

2015-06-30

0.08

2015-03-31

0.08

2014-12-31

0.07

2014-09-30

0.00

2014-06-30

0.00

2014-03-31

0.00

2013-12-31

0.00

2013-09-30

0.00

2013-06-30

0.00

2013-03-31

0.00

2012-12-31

0.00

2012-09-30

0.00

2012-06-30

0.00

2012-03-31

0.00

2011-12-31

0.00

2011-09-30

0.00

2011-06-30

0.00

2011-03-31

0.00

2010-12-31

0.00

2010-09-30

0.01

2010-06-30

0.01

2010-03-31

0.02

2009-12-31

0.02

2009-09-30

0.02

2009-06-30

0.05

2009-03-31

0.04

2008-12-31

0.03

2008-09-30

0.02

2008-06-30

0.01

2008-03-31

0.01

2007-12-31

0.02

2007-09-30

0.02

2007-06-30

0.02

2007-03-31

0.03

2006-12-31

0.03

2006-09-30

0.03

2006-06-30

0.03

2006-03-31

0.03

2005-12-31

0.02

2005-09-30

0.02

2005-06-30

0.07

2005-03-31

0.06

2004-12-31

0.04

2004-09-30

0.04

2004-06-30

0.03

2004-03-31

0.03

2003-12-31

0.09

2003-09-30

0.08

2003-06-30

0.09

2003-03-31

0.28

2002-12-31

0.22

2002-09-30

0.21

Debt to Equity Ratio: 0.09

RIGL Debt to Equity Ratio

RIGL Average Debt to Equity Ratio Chart

RIGL Current vs Average Debt to Equity Ratio Chart

RIGL Debt to Equity Ratio Metrics

RIGL Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

RIGL Debt to Equity Ratio History

Related Metrics